Home / Industry Reports / Pharmaceutical Market Research
Sort By: Title Date Price

Biosimilars - Regulatory Framework and Pipeline Analysis

Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially. All the countries are focusing on reducing the healthcare expenditure and biosimilars compliments to this goal.

$2995 Read More

Opioids Market Overview to 2023 - Opioids in Emerging Markets

The report provides analysis of new developments that will have a strong bearing on the use of opioids in pain management in emerging countries (Argentina, Brazil, China, India, Mexico, Russia and South Africa). Access to opioids is restricted under strict drug control policies and regulations overseeing controlled medicines due to their high abuse potential. Emphasis on restricting access to controlled drugs is much higher in emerging markets than in developed nations, resulting in a level of consumption that is too low to meet pain-control requirements even in cases of terminal illness.

$2995 Read More

Opioids Market Overview to 2023 - Opioids in Western Europe

The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%). Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes.

$2995 Read More

Pediatric Drug Development - Regulatory challenges and commercial opportunities

Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008).  Since the introduction of pediatric legislation there has been a substantial investment in pediatric research and the number of clinical trials performed in children has increased significantly.

$2995 Read More

Alcohol Breathalyzer and Drug Testing Equipment Market, Shares, Strategies, and Forecasts, Worldwide, 2014 to 2020

WinterGreen Research announces that it has published a new study Alcohol Breathalyzer and Drug Testing Equipment Market, Shares, Strategies, and Forecasts, Worldwide, 2014 to 2020.  The 2014 study has 593 pages, 202 tables and figures.  Worldwide markets are poised to achieve significant growth as law enforcement and companies get more businesses test for substance abuse.

$3900 Read More

Adaptive Licensing - A Holistic Approach to Drug Development and Regulation

Adaptive Licensing (AL) is a flexible approach to drug development and regulation, with two live pilot schemes accepted by the European Medicines Agency (EMA). The system acknowledges that levels of uncertainty will always surround innovative treatments. An initial license is granted at an earlier stage than possible under the traditional system, with less clinical information from Randomized Controlled Trials (RCTs).

$2996 Read More

Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related. There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients.

$3900 Read More

Vaccine Development Strategies - Refocusing Efforts to Address New Challenges

Vaccines are one of the most important healthcare advances and have saved millions of lives through immunizing against some of the most deadly diseases. With protection against a number of key viral and bacterial diseases now effectively generated, vaccine R&D is turning to areas of unmet need. Preventative vaccination in adults and against pathogens that affect the developing world is increasingly becoming a focus. Research into therapeutic vaccination for patients already affected by a disease is also gathering pace.

$3900 Read More

Research and Investment Forecast Evaluation of Chinas Enteral Nutrition Preparation Market from 2015 to 2020

5. Development of Enteral Nutrition Preparation in China 5.1 Market Status Quo and Forecast Enteral nutrition preparations are the main varieties in enteral nutrition support treatment. The oral enteral nutrition emulsion and suspension include TPF、TP、TPF-T and TP-HE etc different formulas. The main manufacturers are Sino-Swed Pharmaceutical Corp, Ltd. (SSPC)  and Nutricia (Wuxi), the former mainly includes such brands as: Fresubin Energy Fibre, Fresubin, Supportan and Fresubin MCT 750; while the later mainly includes Nutrison fibre, Nutrison, Peptisorb Liquid and Diason etc brands. In China, the clinical nutrition market started in 1960s-70s. After entered into China market in 1982, China-Germany joint venture Sino-Swed Pharmaceutical is the

$2000 Read More

Telemedicine - The Future is Now for Moving Telemedicine into Mainstream Treatment

Telemedicine is a creation of the 20th century. First used primarily for military and space applications, it has been becoming more widespread in use in recent years. There are three main types of telemedicine applications: store-and-forward, remote monitoring and interactive services. Interest in telemedicine is growing globally, particularly in the fields of teleradiology, telepathology and teledermatology. Globally, cost is seen as the major barrier to telemedicine programs. In the US, telemedicine has been promoted as a way to serve rural populations, but in the next few years it is expected to spread to a much wider patient base.

$3900 Read More

Immunotherapy Development Strategies - An Evolving Market with Significant Potential but with Challenging Hurdles to Overcome

Although immunotherapy was first recognized over 100 years ago, it has only become an important therapeutic tool in recent decades. The immune system can be harnessed in one of several ways to tackle various diseases such as cancer, infection, auto-immune disease and inflammatory diseases. The complexity of the immune system has led to some intrinsic obstacles with clinical research, particularly in relation to targeting the right genes, identifying the appropriate patient population and accessing internal tissues for testing.

$3900 Read More

The Politics of Pharma - Washington, States and the Courts Impact on the Industry

Politics have a greater direct effect on the pharmaceutical industry than almost any other in the US, and correspondingly, pharma makes considerable investments in election campaigns. The November elections kept the face of Washington the same, with the re-election of President Obama, Democratic control of the Senate and Republican control of the House. However, the outcome of the elections will still impact the industry in a variety of ways. The Medical Device Excise Tax, a component of the 2010 health care reform legislation, survived a pre-election Congressional effort at repeal, but a coalition of House Republicans and Democrats from key states are looking to try again.

$3900 Read More

R&D Productivity - The State of Research and Development in the BioPharmaceutical Industry

As blockbusters go off patent and the pool of marketed products supporting pharmaceutical Research & Development (R&D) decline, questions about the future of R&D in the pharmaceutical and biotech industry arise. Where will funding come from? Is spend decreasing? If spend is decreasing, what impact is this having on R&D? What can be done to encourage innovation in the biotech and pharmaceutical industry? Is the biotech model of R&D better for innovation than the traditional pharmaceutical model? Gauging the overall growth of R&D in the pharmaceutical and biotech industry proves challenging in regards to stipulating the appropriate definition of variables by which this is measured.

$3900 Read More

Companion Diagnostics - Streamlining drug development and advancing personalized medicine

Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around for many years, it is only with the advent of companion diagnostics that personalized healthcare has started to gain ground. Companion diagnostics can be used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize risk

$3900 Read More

Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.

$3900 Read More

Oncology Development Strategies - Considerable commercial potential but specific needs must be addressed

The oncology therapeutic area has seen significant development and advances over the last decade. However, oncology has one of the lowest overall clinical success rates of all therapy areas with only a third of oncology drugs that get to Phase III proceeding to approval. There are a number of factors that will affect the likelihood of success in oncology drug development and these must be taken into consideration when designing the clinical development plan. Oncology clinical trials tend to be more complex than those in other therapy areas, largely due to the number of endpoints that can be utilized, the growing need for adaptive trial design and the types of patients that are eligible for the clinical studies.

$3900 Read More

Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome

Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacture an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010. Of the emerging markets, the BRIC markets offer the greatest potential for pharmaceutical growth, especially in biologics which represent a relatively untapped market in these countries. It is expected the BRIC markets will account for over 25% of global biologic revenues by 2015.

$3900 Read More

Electronic Health Records - Charting the Future of Health Care

Electronic Health Records have been in limited use since the 1960s, but their adoption received a major boost when they became more of a focus for the US government. In 2004, President Bush put forth the goal of having every American covered by an EHR within 10 years. In 2009, President Obama added the key element of funding under the American Recovery and Reinvestment Act. The EHR Meaningful Use Incentive programs funded under the ARA were further bolstered by programs in the 2010 health care reform legislation which promoted Accountable Care Organizations. After the results of the November elections and the Supreme Courts ruling upholding the individual mandate, the future for health care reform would look more sure.

$3900 Read More

The Digital Patient - A Snapshot of the Digital Landscape of Patients and Caregivers

The advent of mobile phones and other devices has opened up new channels for pharmaceutical marketers to reach patients and caregivers. The Pharma industry as a whole is late to the digital game so logically patients and caregivers have pre-existing expectations of the digital experience. Digital enables brands to deliver highly targeted information in a variety of forms. It creates the setting for a brand experience versus a promotional moment. This is a tremendous opportunity but not one without challenges one of the biggest obstacles being lack of clear direction from the FDA around appropriate use of social media.

$3900 Read More

Emerging Pharmaceutical Technologies - Stem cells

The report, Emerging Pharmaceutical Technologies - Stem cells has been written to support corporate strategy, new product development, business development, and R&D teams through its analysis of the trends being seen and the innovations taking place in this fast moving area. This report will support the corporate strategies and key decisions being made in this area through its analysis, insights, case studies, and company profiles included.

$3900 Read More

Accountable Care Organizations - A Building Block for the Future of Health Care

The Accountable Care Act promoted ACOs through a variety of programs: Comprehensive Primary Care Initiative, Partnerships for Patients Initiative, Pioneer and Advanced Payment ACO Models and Medicare Shared Savings Program for ACOs. The central program is the Medicare Shared Savings Program, under which ACOs gradually share in the cost savings they achieve through providing coordinated and consistent care to groups of Medicare beneficiaries while meeting quality targets. The focus of ACOs is coordinated care, ease-of-access, care management models, evidence-based care, technology use for data management, and clinical integration.

$3900 Read More

Clinical Development and Trial Design - Developing a Coherent Approach From Beginning to End

A good clinical development plan will ensure success throughout the product lifecycle. In todays cost constrained environment, the clinical development plan can help refine the trial process, encouraging cost and time efficiencies and ensuring a streamlined process throughout. The clinical development plan ties together all aspects of product development, enabling an incorporated approach to the clinical and commercial rationale of product development. A variety of approaches should be adopted to ensure a robust clinical development plan is developed.

$3900 Read More

Diversification in the Pharmaceutical Industry - Essential For Survival or an Unnecessary Distraction?

Pharmaceutical companies face the dual threats of industry specific difficulties driven by the innovation crisis, patent expiries and healthcare reform, coupled with the more generalized issues caused by the continuing global economic slowdown. The industry remains split on whether diversification or specialization is the key to building a successful business model in the face of these difficulties. On one hand some companies believe that diversification is necessary to survive and thrive in the current difficult operating environment and that it offers specific advantages going forward.

$3900 Read More

The Next Generation of Pharmaceutical Marketing Strategies - Understanding All of the Strategic Considerations Needed in the Age of Multiple Stakeholders

Pharmaceuticals save lives. They prevent more serious, life changing conditions, they prevent surgery, and they improve the quality of life for many patients. The environment in which these products are developed and commercialized is in a period of great transformation. Lacking a crystal ball, the industry as a whole is navigating through unchartered waters. Multiple factors are driving the need for industry-wide change. One of the biggest contributors is the escalating cost of healthcare. In an effort to stop and reverse this trend a great emphasis is being placed on improving the delivery of care and outcomes for patients.

$3900 Read More

Pharmaceutical Pricing Strategies - Changing approaches to meet challenging times

The current economic environment has created a number of challenges within the pharmaceutical market, with governments looking to reduce spending on healthcare and drugs. Consequently, prices have come under scrutiny, with many older products having discounts forced upon them and new drugs being subject to increasingly complex assessments in order to obtain the desired price. Novel pricing policies, such as value based pricing and external price referencing, are being employed by governments to regulate pharmaceutical prices and are expected to have a significant impact on prices and profitability in the future.

$3900 Read More

The Payer Landscape in the United States - The Pharmaceutical Industry Faces a Rapidly Changing Marketplace

Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both. That said, private payers, such as regionals, nationals and blues plans, may take the brunt of the reform policies put in place. The health care reform legislation in 2010 was the product of extended debate and compromise. The legislation will mean huge changes for the insurance industry if it is enacted. However, the more controversial aspects of the legislation, particularly the Mandate for health insurance, have resulted in numerous challenges.

$3900 Read More

Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management

Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience. Its potential to rejuvenate R&D pipelines in the future as new technologies emerge compliment its position as a key lifecycle management strategy. Reformulation will continue to be a much used lifecycle management strategy, enabling companies to boost sales before patent expiry and in ideal cases protect sales after generics enter. However in order to achieve this companies must focus increasingly on demonstrating provable benefits, ideally in head to head trials against the original product.

$3900 Read More

Looking at Senior Long-term Care - Where will the market go?

In the last 50 years, long-term care facilities in the US have changed significantly. Many facilities are now Continuing Care Retirement Communities (CCRCs), offering a continuum of care from Independent Living to Assisted Living to Skilled Nursing. Memory Care facilities, for those with Alzheimers Disease or Dementia are often separate facilities, but may be part of a larger CCRC campus. Long-term care is becoming increasingly important as a market with the US population aging. Over 65s are now the fastest growing population group in the US. With the Baby Boomer generation only just beginning to turn 65 in 2011, the next 20 years will see tremendous growth in the long-term care population.

$3900 Read More

Risk Evaluation and Mitigation Strategies - Adaptation in an evolving system

As an evolution of this process, the agency established the Risk Evaluation and Mitigation Strategies (REMS) program in 2008. Products can be approved with a Medication Guide only REMS, a Communication Plan REMS which incorporates a Medication Guide together with educational materials for providers or it can require Elements to Assure Safe Usage (ETASU). There has been substantial criticism of the current REMS system from pharmaceutical companies, as well as from providers and dispensers. The FDA is moving to address some of these criticisms by trying to establish greater standardization across the system.

$3900 Read More

Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation

Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant.

$6995 Read More

Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

GBI Research, the leading business intelligence provider, has released its latest research, ""Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth"", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and

$4995 Read More

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation

The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. GBI Research’s analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets. This exceptional first-in-class innovation is largely due to the high number of first-in-class products solely targeting the dystrophin gene, which is the primary genetic cause of DMD and BMD. 

$6995 Read More

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs

GBI Research, the leading business intelligence provider, has released its latest research, ""Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs"", which provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan.

$4995 Read More

Global Continuous Glucose Monitoring System Market by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Size, Opportunities, Segmentation and Forecast 2015 – 2021

Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved

$4000 Read More

Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition

Iron deficiency anemia is the most common form of anemia throughout the world. It is estimated that two billion people suffer from iron deficiency anemia worldwide. To address iron deficiency, iron therapy is important being the critical factor in the production of red blood cells. Around 4.5 million Americans are diagnosed and suffering from iron deficiency anemia (IDA). Generally, daily oral iron is the first line therapy for most IDA patient but for many patients oral iron therapy fails as a consequence of compliance, efficacy and side effects like constipation and gastro intestinal disorders.

Global Hemophilia Market Report: 2015 Edition

Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions. The main treatment is called replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected into a vein.

The US Specialty Pharmaceutical Market Report: 2015 Edition

Specialty pharmaceuticals are typically high-cost, scientifically engineered drugs used to treat complex, chronic conditions that require special storage, warranting special handling, and temperature-control monitoring. These products are often manufactured for small populations of people suffering from somewhat rare, life-threatening and debilitating diseases. The specialty pharmaceuticals are mostly injectable or infused medicines but may also encompass oral medications.

Dexmedetomidine - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$9300 Read More

Ferric carboxymaltose - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$6200 Read More

Lanreotide - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$9300 Read More

Vildagliptin - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$7500 Read More

Cabozantinib - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$7500 Read More

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Chinese pharmaceutical packaging market reached RMB72 billion, up 10.6% from a year earlier.

$1550 Read More

Nilotinib - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Nilotinib  Nilotinib indications: Treatment of Philadelphia chromosome positive chronic myeloid leukaemia, optionally in combination with erythropoietin, G-CSF, hydroxyurea or Anagrelide Nilotinib innovator: Novartis (Tasigna) Examples of information found in this online report include:

$1200 Read More

Ceftolozane - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Ceftolozane Ceftolozane indications: Treatment of serious Gram-negative bacterial infections Ceftolozane innovator: Cubist Examples of information found in this online report include: Includes key patent publications for 44 countries (see list below) Contains SPC protection for every EU state plus patent term extensions in other countries Data

$1200 Read More

Ceftobiprole - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Ceftobiprole Ceftobiprole indications: Treatment for complicated skin and skin structure infections Ceftobiprole innovator: Janssen (Zeftera, Zevtera) Examples of information found in this online report include: Includes key patent publications for 44 countries (see list below) Contains SPC protection for every EU state plus patent term

$1200 Read More

Deferasirox - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Deferasirox Deferasirox indications: Treatment of chronic iron overload due to blood transfusions or in patients with non-transfusion dependent thalassaemia; Management of chronic iron overload in transfusion-dependent anaemias Deferasirox innovator: Novartis (Exjade) Examples of information found in this online report include:

$1200 Read More

Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

The report entitled „Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis“ published in January 2014 is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms.

$2873 Read More

Competitor Analysis ErbB / Her Receptor Antagonists

The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Subscription to La Merie Publishing’s proprietary Antibody Database provides online access to information about more than 2,400 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their Technology (e.g. antibody-drug conjugate, bispecific, isotype, phage display) Target (e.g. Her2, CD20, TNF, PD-1/PD-L1) Pipelines (selected by target, therapeutic area, company, technology) Sales (for marketed antibodies) R&D Phase (clinical phases, market, preclinical) Territory (countrywise) Therapeutic Area (e.g. infectious, oncology, gastrointestinal)

$1705 Read More

Antibody Technologies and Attrition Rates - an industry analysis 2013

The report “Antibody Technologies and Attrition Rates – an industry analysis 2013” is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to February 28, 2013.

$2781 Read More

Genitourinary Deals and Alliances of 2014

The Genitourinary Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.

$1495 Read More

Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition

The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope.

$2350 Read More

Risk Sharing and Other Forms of Managed Entry Agreements for Medicines, Worldwide

Managed entry agreements apply to an increasing number of new, innovative drugs in a growing number of markets. They are designed to share the risk between the manufacturer and the payer, consequent on uncertainties - usually at launch - about the product’s value (clinical- and cost-effectiveness), budget impact and/or utilisation to optimise performance, whilst at the same time allowing patient access. For many products considered costly they are almost essential to achieve reimbursement where health technology assessment is applied.

$1050 Read More

Japan Pharmaceutical Pricing & Distribution Market , 2012 Update

No serious pharmaceutical company can afford to ignore Japan, a $120 billion market, the second-largest in the world. It remains a tough and highly competitive market to crack, however, with the environment for developing and marketing medicines dominated by price.

$1400 Read More

Pharmaceutical Pricing & Distribution in Japan, 2010 Update

The author’s 2008 major title ‘Pharmaceutical Pricing & Distribution in Japan’ was described by PhRMA Japan as ‘a superb report…to understand Japan there is nothing better’. His new report packs all the essentials needed to optimise market access and life cycle management into 60 pages and offers tremendous value.

Orphan Drugs Market in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition

The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope.

$2300 Read More

Market Access Korea: Breaking into the Developed World's Fastest Growing Pharmaceutical Market

South Korea as a country has been an economic success story and the origin of much cutting edge technology, but its pharmaceutical market can now also be given ‘Asian tiger’ status. The past four years have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS forecasts CAGR of 6.5% from 2010 through 2015, making Korea the fastest growing developed market for medicines in the world.

$1380 Read More

Inflammatory Bowel Disease Partnering 2010-2015

The report provides an analysis of inflammatory bowel disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors inflammatory bowel disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Asia-Pacific Orphan Drugs Market : From Designation to Pricing, Funding & Market Access

A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of rare disease treatments.

$2320 Read More

OTC Drugs Markets in China

China's demand for OTC Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades.

$4000 Read More

Neuropathy Partnering 2010-2015

The report provides an analysis of neuropathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuropathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Big pharma Deals and Alliances of 2014

The Big Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.

$1495 Read More

Pharmaceutical Deals and Alliances of 2014

The Pharmaceutical Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.

$1495 Read More

Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19)

The report titled “Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses key opportunities in the market and outlines the factors that are and will be driving growth of the industry. Growth of the overall CHC industry has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. An insight into strategic issues affecting key brands on the market is provided followed by an analysis of the leading companies in the hormonal contraceptives market. The report also analyzes the key CHC products in pipeline.

Academic-Non-Profit Deals and Alliances of 2014

The Academic/Non-Profit Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.

$1495 Read More

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 199 tables & figures within 153 pages.

$2754 Read More

Pharmaceutical Market China Q2 2013

Pharmaceutical Industry China Q2·2013 – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments.

$2700 Read More

Obsessive-Compulsive Disorder-API Insights, 2014

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.

$1250 Read More

Generic Pharma Deals and Alliances of 2014

The Generic Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.

$1495 Read More

Specialty Pharma Deals and Alliances of 2014

The Specialty Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.

$1495 Read More

Pharmaceutical Market India Q2 2013

Pharmaceutical Market India: A Comprehensive Industry Analysis provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 330 tables & figures.

$2700 Read More

Merger and Acquisition Deals and Alliances of 2014

The Merger and Acquisition Deals of 2014 provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2014.

$1495 Read More

Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline Insights, 2015

DelveInsights, Ankylosing Spondylitis (Bekhterev's Disease)-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this Ankylosing Spondylitis (Bekhterev's Disease). A key objective of DelveInsights report is to establish the understanding for all the pipeline drugs that fall under Ankylosing Spondylitis (Bekhterev's Disease). The report provides information on the therapeutic development based on the Ankylosing Spondylitis (Bekhterev's Disease) providing licensing, chemical, technology information and comparative analysis at various stages. DelveInsights Report is assessing the Ankylosing Spondylitis (Bekhterev's Disease) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

$1250 Read More

Enterobacteriaceae Infections-Pipeline Insights, 2015

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

$1250 Read More

Personalized Medicine & Companion Diagnostic Market Q2 2013

Personalized Medicine and Companion Diagnostic Market- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment” provides you with a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 261 tables & figures over 205 pages.

$3766 Read More

Pharmaceutical Industry in China Q3 2013 - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

$2754 Read More

India Pharmaceutical Market: A Comprehensive Industry Analysis Q3 2013

Pharmaceutical Market: India, A Competitive Industry Analysis Q3 2013” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities. 

$2593 Read More

BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 154 tables & figures.

$2593 Read More

Personalized Medicine- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 239 tables & figures.

$3617 Read More

China Liver Disease Drug Industry 2015 Analysis Report

Liver damage can cause a series of diseases. According to the different etiology, liver disease can generally be divided into viral liver disease and non-viral liver disease. Non-viral hepatitis mainly includes alcoholic hepatitis, drug-induced hepatitis or toxin-induced hepatitis, metabolism abnormal hepatitis, hepatic calculus, etc.

$3500 Read More

Local Anesthetic Effect-Pipeline Insights, 2015

DelveInsights, Local Anesthetic Effect-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this Local Anesthetic Effect. A key objective of DelveInsights report is to establish the understanding for all the pipeline drugs that fall under Local Anesthetic Effect. The report provides information on the therapeutic development based on the Local Anesthetic Effect providing licensing, chemical, technology information and comparative analysis at various stages.

$1250 Read More

Global Depression Therapy & Treatment Market – Depression drugs and devices, Anxiety Disorders,  SSRIs, Fischer wallace stimulator, Transcranial magnetic stimulation, Psychoanalysis, Cognitive Behavior, Psychodynamic, Electroconvulsive Pipeline Analysis, Physical Therapy Market, Forecast 2014 – 2021

Depression treatment market is segmented on the basis of antidepressants drugs, devices and therapies. Antidepressants are the largest market segment. Antidepressants are the most popular treatment methods. Every year more than five billion prescriptions are written globally.

$4000 Read More

Melanoma-API Insights, 2015

DelveInsights, Melanoma-API Insights, 2015,report provides Melanoma drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Melanoma. The Report provides the India and China API Manufactures who are driving the current API Market.

$1250 Read More

Zollinger-Ellison Syndrome (Gastrinoma)-API Insights, 2015

DelveInsights, Zollinger-Ellison Syndrome (Gastrinoma)-API Insights, 2015,report provides Zollinger-Ellison Syndrome (Gastrinoma) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Zollinger-Ellison Syndrome (Gastrinoma). The Report provides the India and China API Manufactures who are driving the current API Market.

$1250 Read More

Herpes Zoster Ophthalmicus-API Insights, 2015

DelveInsights, Herpes Zoster Ophthalmicus-API Insights, 2015,report provides Herpes Zoster Ophthalmicus drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Herpes Zoster Ophthalmicus. The Report provides the India and China API Manufactures who are driving the current API Market.

$1250 Read More

Pernicious Anemia-API Insights, 2015

DelveInsights, Pernicious Anemia-API Insights, 2015,report provides Pernicious Anemia drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Pernicious Anemia. The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsights report also highlights the patent, patent exclusivity information and competitive landscape

$1250 Read More

Retinitis Pigmentosa (Retinitis)-API Insights, 2015

DelveInsights, Retinitis Pigmentosa (Retinitis)-API Insights, 2015,report provides Retinitis Pigmentosa (Retinitis) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Retinitis Pigmentosa (Retinitis). The Report provides the India and China API Manufactures who are driving the current API Market.

$1250 Read More

Polycystic Kidney Disease-Pipeline Insights, 2015

DelveInsights, Polycystic Kidney Disease-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this Polycystic Kidney Disease. A key objective of DelveInsights report is to establish the understanding for all the pipeline drugs that fall under Polycystic Kidney Disease. The report provides information on the therapeutic development based on the Polycystic Kidney Disease providing licensing, chemical, technology information and comparative analysis at various stages. DelveInsights Report is assessing the Polycystic Kidney Disease therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

$1250 Read More

Thymus Cancer-Pipeline Insights, 2015

DelveInsight’s, “ Thymus Cancer-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this Thymus Cancer. A key objective of DelveInsight’s report is to establish the understanding for all the pipeline drugs that fall under Thymus Cancer. The report provides information on the therapeutic development based on the Thymus Cancer providing licensing, chemical, technology information and comparative analysis at various stages. 

$1250 Read More

Absence Seizure-API Insights, 2015

DelveInsights, Absence Seizure-API Insights, 2015,report provides Absence Seizure drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Absence Seizure. The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsights report also highlights the patent, patent exclusivity information and competitive landscape.

$1250 Read More

Cerebral Palsy-API Insights, 2015

DelveInsights, Cerebral Palsy-API Insights, 2015,report provides Cerebral Palsy drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Cerebral Palsy. The Report provides the India and China API Manufactures who are driving the current API Market.

$1250 Read More

Optimizing Treatment for Bone Metastases in Patients with Advanced Cancers

Understand current practice patterns related to bone metastases in patients with advanced cancers. Patient specific unfolding case scenarios presented to 174 high-prescribing oncologists on the treatment of bones metastases in patients with advanced stages of cancer including breast, renal cell carcinoma, and prostate. The survey was presented for their responses on clinical decisions.

$2999 Read More

US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma

Patient specific case scenario on advanced non-Hodgkin’s lymphoma in a situation involving a patient with Stage IIIA Asymptomatic Indolent Lymphoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals.

$2999 Read More

Chronic Urticaria Or Hives-Pipeline Insights, 2015

DelveInsights, Chronic Urticaria Or Hives-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this Chronic Urticaria Or Hives. A key objective of DelveInsights report is to establish the understanding for all the pipeline drugs that fall under Chronic Urticaria Or Hives. The report provides information on the therapeutic development based on the Chronic Urticaria Or Hives providing licensing, chemical, technology information and comparative analysis at various stages. DelveInsights Report is assessing the Chronic Urticaria Or Hives therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

$1250 Read More

US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma

Two patient specific case scenarios on advanced non-Hodgkin’s lymphoma involving patients with a) relapsed large cell lymphoma and b) large cell lymphoma with compromised cardiac function that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal.

$2999 Read More

Neurofibroma-Pipeline Insights, 2015

DelveInsights, Neurofibroma-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this Neurofibroma. A key objective of DelveInsights report is to establish the understanding for all the pipeline drugs that fall under Neurofibroma. The report provides information on the therapeutic development based on the Neurofibroma providing licensing, chemical, technology information and comparative analysis at various stages. DelveInsights Report is assessing the Neurofibroma therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. In addition to this, thereport has covered the key players and their financial details.

$1250 Read More

US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

A patient specific case scenario on advanced non-Hodgkin’s lymphoma involving a patient with stage IV follicular B-cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal: Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal patient care Confidence in treatment

$2999 Read More

Vitiligo-Pipeline Insights, 2015

DelveInsight’s, “ Vitiligo-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this Vitiligo. A key objective of DelveInsight’s report is to establish the understanding for all the pipeline drugs that fall under Vitiligo. The report provides information on the therapeutic development based on the Vitiligo providing licensing, chemical, technology information and comparative analysis at various stages. DelveInsight’s Report is assessing the Vitiligo therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

$1250 Read More

US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma

Experience real patient situations that progressively unfold, presented to a representative sample of 158 US oncologists who manage 11 or more patients monthly with non-Hodgkin’s lymphoma. Oncologists were presented with four patient case scenarios and asked to respond to open-ended questions concerning their choices of treatment regimens, factors that influenced their decisions, and barriers to optimal patient management. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types.

$8900 Read More

Pharmaceutical